Coronary vasoconstriction in experimental myocardial ischemia

Area of Science:

• Cardiovascular Physiology
• Renal Physiology
• Pharmacology

Background:

• Myocardial ischemia is often assumed to cause maximal coronary vasodilation.
• The role of the renin-angiotensin system in regulating coronary tone during ischemia is not fully understood.

Purpose of the Study:

• To investigate the coexistence of coronary arteriolar constriction mediated by the renin-angiotensin system and myocardial ischemia.
• To evaluate the therapeutic potential of ACE inhibitors in experimental myocardial ischemia.

Main Methods:

• Coronary stenosis was simulated by perfusing the left anterior descending coronary artery at varying pressures.
• Myocardial ischemia was identified by lactate production.
• Effects of adenosine, indomethacin, saralasin, and captopril on coronary conductance and infarct size were assessed.

Main Results:

• Low coronary pressure induced myocardial ischemia with coronary constriction, not maximal dilation.
• Plasma renin activity increased during ischemia.
• Saralasin and captopril demonstrated coronary vasodilator effects.
• Captopril reduced infarct size, improved flow, and preserved function during ischemia.

Conclusions:

• Myocardial ischemia does not lead to maximal coronary vasodilation.
• The renin-angiotensin system is activated during ischemia and contributes to coronary constriction.
• Captopril exhibits beneficial effects in experimental myocardial ischemia, suggesting a therapeutic role for ACE inhibitors.